Inetetamab
- Generic Name
- Inetetamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
- Indication
本品用于HER2阳性的转移性乳腺癌。与长春瑞宾联合治疗接受过1个或多个化疗方案的转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Pyrotinib and Vinorelbine Tartrate Capsules With or Without Inetetamab for First Line Treatment in Patients With Trastuzumab-resistant HER2-positive Advanced Breast Cancer
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 100
- Registration Number
- NCT04963595
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- Peking Union Medical College
- Target Recruit Count
- 270
- Registration Number
- NCT04736589
- Locations
- 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2020-12-23
- Target Recruit Count
- 71
- Registration Number
- NCT04681911
- Locations
- 🇨🇳
Sun Yat Sen Memorial Hospital，Sun Yat sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath